TARGETING ONE

TARGETING ONE, established in 2015, focuses on the independent innovation of molecular diagnostic technologies and their application in major disease transformations. It has a high-level R&D team in the fields of instruments, chips, materials, reagents, and software. The company has developed rapidly, applying for more than 100 domestic and international patents and being granted over 40 patents. It continuously publishes academic papers in authoritative journals and undertakes national scientific research funds. The digital PCR system independently developed by the company based on its intellectual property rights has won the Gold Award for Excellent Innovative Products in China's in vitro diagnostics for two consecutive years and was honored as the overall champion of the Zhongguancun International Frontier Science and Technology Innovation Competition. Adhering to the concept of "Innovative Precision, Dedicated to You," the company is committed to developing multi-index, high-throughput, automated, contamination-proof, and low-cost molecular diagnostic technologies, striving to become a leading enterprise in life sciences and molecular diagnostics, serving life sciences, precision medicine, drug development, and health management.